Molecular Partners AG Presents Positive Data from Completed Phase 1 Trial of MP0317 (FAP X CD40 DARPin) Monotherapy in Patients with Advanced Solid Tumors At ASCO 2024

Molecular Partners AG announced it had presented the final data from its Phase 1 dose-escalation study of MP0317 at the American Society of Clinical Oncology Annual Meeting 2024, held in Chicago, IL,...

Related Keywords

United States ,Chicago ,Illinois ,American , ,American Society Of Clinical Oncology ,Molecular Partners ,American Society ,Clinical Oncology ,Annual Meeting ,